FLT3
Thermo Fisher Scientific's IonTorrent Genexus platform can provide cancer panel results in about a day, but data on clinical impact of the fast turnaround has not yet been produced.
Invivoscribe Files FDA Supplemental PMA for CDx Test to Select AML Patients for Daiichi Sankyo Drug
The assay will be used to identify FLT3-ITD-positive AML patients who can benefit from treatment with Daiichi Sankyo's quizartinib.
Invivoscribe, Kronos Bio Partner on Companion Diagnostic Test for Leukemia Drug
The companion diagnostic assay would identify mutations in the NPM1 gene, which Kronos Bio is targeting with its investigational drug entospletinib.
Japanese Regulators Approve Invivoscribe Assay as CDx for Daiichi Sankyo AML Drug
The LeukoStrat CDx FLT3 Mutation Assay can now be used in Japan as the CDx for quizartinib for the treatment of FLT3-ITD positive relapsed or refractory AML.
Researchers used Mission Bio's Tapestri assay to identify and monitor the evolution of cancer mutations in acute myeloid leukemia in response to targeted treatment.